Composition
- Active substance
- ximelagatran
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ximelagatran 36 mg film coated tablets
- Active substance
- ximelagatran
- Therapeutic area
- Atrial Fibrillation
- Marketing authorisation holder
- AstraZeneca
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/000702
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No